November 11, 2025 a 08:39 am
ABT: Analysts Ratings - Abbott Laboratories
Abbott Laboratories, a global player in healthcare products, showcases a strong diversified portfolio across pharmaceuticals, diagnostics, nutrition, and medical devices. The stock performance has drawn attention from various analysts, indicating a balanced yet optimistic sentiment. As of the latest data, the predominant market sentiment leans towards a buying opportunity, which is supported by the consistent projections and advances in Abbott's sector movements.
Historical Stock Grades
| Recommendation | Number of Analysts | Score |
|---|---|---|
| Strong Buy | 6 | |
| Buy | 15 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The overall sentiment has shown slight variations over the last few months, with a minor reduction in Strong Buy recommendations. Interestingly, Hold recommendations have slightly increased, suggesting a cautious yet not overly pessimistic outlook.
- Overall, a stable number of Buy recommendations, indicating sustained confidence.
- No Sell or Strong Sell recommendations in the latest month, reinforcing a positive outlook.
- A consistent number of analysts maintain the Hold position, highlighting market caution.
Percentage Trends
A conspicuous trend in the last year is the shift from Strong Buy to Buy and Hold, suggesting a more conservative approach by analysts. The hold ratings increased by a modest percentage, indicating stable but cautious confidence.
- November 2025: Strong Buy at 20%, Buy at 50%, Hold at 26.67%, No Sell or Strong Sell ratings.
- Similar distributions were noted from previous months, with minor variances.
- The past 12 months saw a trend towards more balanced ratings vs. overly enthusiastic buy signals.
Latest Analyst Recommendations
The latest analyst recommendations illustrate a recurring pattern of maintaining the current stock ratings, reflecting steadiness in the analysts' views.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-17 | Overweight | Overweight | Barclays |
| 2025-10-16 | Overweight | Overweight | Wells Fargo |
| 2025-10-16 | Outperform | Outperform | RBC Capital |
| 2025-10-16 | Outperform | Outperform | Evercore ISI Group |
| 2025-10-16 | Outperform | Outperform | Raymond James |
Analyst Recommendations with Change of Opinion
Recent changes in analysts' opinions predominantly involve upgrades, indicating a shift towards a more positive future outlook for Abbott Laboratories.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-18 | Buy | Hold | Jefferies |
| 2023-07-21 | Peer Perform | Underperform | Wolfe Research |
| 2023-07-20 | Peer Perform | Underperform | Wolfe Research |
| 2021-10-27 | Overweight | Neutral | Atlantic Equities |
| 2021-10-26 | Overweight | Neutral | Atlantic Equities |
Interpretation
The current market sentiment towards Abbott Laboratories suggests a stable but cautiously optimistic outlook. The move from Strong Buy to more balanced Buy and Hold recommendations indicates a more tempered market view, likely reflecting external market conditions or internal company strategies. While some analysts have upgraded their recommendations, the overall movement remains generally positive and steady. The absence of Sell recommendations points to enduring confidence in Abbott's long-term potential.
Conclusion
Abbott Laboratories continues to exhibit a robust performance hingeing on its diversified product offerings across various sectors. The analysts' steady recommendations underpin an overarching confidence in the stock's medium to long-term prospects. However, the moderation in Strong Buy recommendations warrants a measured approach moving forward. As the global healthcare landscape evolves, ABT's adaptability and innovation will be pivotal in navigating future challenges and capitalizing on opportunities. Investors and analysts alike may find its market position reassuring, provided external factors remain stable.